Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3761304rdf:typepubmed:Citationlld:pubmed
pubmed-article:3761304lifeskim:mentionsumls-concept:C0007209lld:lifeskim
pubmed-article:3761304lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3761304lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:3761304pubmed:issue10lld:pubmed
pubmed-article:3761304pubmed:dateCreated1986-11-19lld:pubmed
pubmed-article:3761304pubmed:abstractTextWe discovered that 6 (N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide) is a potent positive inotrope in dogs, and we have prepared several lactam analogues of this agent. These included 16 (1,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one), 32 (the analogous quinolin-2-one), and 37 (the analogous benzazepin-2-one). The inotropic ED50's of these compounds were 24, 3.3, and 5.2 micrograms/kg, respectively, after iv administration to pentobarbital-anesthetized dogs. Compound 20 (LY195115, 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-i ndol-2- one), the geminal dimethyl analogue of 16, was 3.5-fold more potent than 16 when administered iv (ED50 = 6.8 micrograms/kg). However, the most profound effect of the geminal alkyl substitution was on oral activity. The approximate ED50's of 20 and 16 after oral administration to conscious dogs were 25 and 400 micrograms/kg, respectively. The increase in contractility produced by 25 micrograms/kg of 20 was maximally sustained in excess of 8 h. Thus, 20 is one of the most potent and long-acting oral inotropes described to date.lld:pubmed
pubmed-article:3761304pubmed:languageenglld:pubmed
pubmed-article:3761304pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3761304pubmed:citationSubsetIMlld:pubmed
pubmed-article:3761304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3761304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3761304pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3761304pubmed:statusMEDLINElld:pubmed
pubmed-article:3761304pubmed:monthOctlld:pubmed
pubmed-article:3761304pubmed:issn0022-2623lld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:KauffmanR FRFlld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:WilsonHHlld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:HayesJ SJSlld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:RobertsonD...lld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:PollockG DGDlld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:KrushinskiJ...lld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:BeedleE EEElld:pubmed
pubmed-article:3761304pubmed:authorpubmed-author:WyssVVlld:pubmed
pubmed-article:3761304pubmed:issnTypePrintlld:pubmed
pubmed-article:3761304pubmed:volume29lld:pubmed
pubmed-article:3761304pubmed:ownerNLMlld:pubmed
pubmed-article:3761304pubmed:authorsCompleteYlld:pubmed
pubmed-article:3761304pubmed:pagination1832-40lld:pubmed
pubmed-article:3761304pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:meshHeadingpubmed-meshheading:3761304-...lld:pubmed
pubmed-article:3761304pubmed:year1986lld:pubmed
pubmed-article:3761304pubmed:articleTitleDihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.lld:pubmed
pubmed-article:3761304pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3761304pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:3761304lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3761304lld:pubmed